Latest Farletuzumab Stories
Clinical Study (003-011) to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination with Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD)
New comprehensive research report “Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies”
BURLINGAME, Calif., July 26, 2011 /PRNewswire/ -- Epitomics, Inc., a biotechnology company commercializing the next generation of antibodies based on its groundbreaking Rabbit Monoclonal (RabMAbÂ®) technology, today announced the Company has now launched 23 novel cancer-related antibodies that were developed through a partnership with the National Cancer Institute's Center for Cancer Research.
EXTON, Penn., July 1 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced a research collaboration agreement with Synageva BioPharma Corporation to express and develop therapeutic monoclonal antibodies for the potential treatment of various forms of cancer and infectious disease. Under the terms of the agreement, Synageva will use its proprietary Synageva Expression Platform (SEP(TM)) technology and its expertise to produce and develop a...
- a slit in a tire to drain away surface water and improve traction.